Please login to the form below

Not currently logged in
Email:
Password:

Forteo

This page shows the latest Forteo news and features for those working in and with pharma, biotech and healthcare.

Trulicity’s ascent lifts Lilly

Trulicity’s ascent lifts Lilly

These new medicines will be needed to offset continued decline in its older blockbuster medicines, Cialis and Forteo and Humulin, which all earned over $1bn in 2018, but will start to

Latest news

  • FDA rejects Amgen's osteoporosis hope romosozumab FDA rejects Amgen's osteoporosis hope romosozumab

    Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak, ... Forteo is heading for patent expiry, so Radius'

  • CHMP recommends Merck & Co's Lantus biosimilar CHMP recommends Merck & Co's Lantus biosimilar

    Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo. EMA advisors have recommended Merck &Co's biosimilar version of Lantus, Sanofi's blockbuster basal insulin product, be approved. ... Forteo biosimilars. Meanwhile, the CHMP this

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo

  • Amgen and UCB's romosozumab hits goals in male osteoporosis Amgen and UCB's romosozumab hits goals in male osteoporosis

    Forteo is widely used in osteoporosis therapy and brought in sales of around $1.35bn last year. ... Amgen and UCB previously reported data showing romosozumab was superior to Forteo, which also requires daily dosing by injection.

  • Amgen says romosozumab on track for 2016 filing Amgen says romosozumab on track for 2016 filing

    Amgen and UCB have previously reported data showing romosozumab was superior to Eli Lilly's parathyroid hormone-based Forteo (teriparatide), which requires daily dosing by injection. ... Forteo is widely used in osteoporosis therapy and brought in sales

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....